Risk Factors for New-Onset Diabetes Mellitus in Patients Receiving Protease Inhibitor Therapy

Risk Factors for New-Onset Diabetes Mellitus in Patients Receiving Protease Inhibitor Therapy

BACKGROUND: Metabolic complications including diabetes mellitus (DM) have been associated with protease inhibitor (PI) therapy. Risk factors for the development of DM are not well-defined.

Saved in:

Bibliographic Details
Main Authors:	Christine A Hughes, Richard P Cashin, Dean T Eurich, Stan Houston
Format:	Article
Language:	English
Published:	Wiley 2005-01-01
Series:	Canadian Journal of Infectious Diseases and Medical Microbiology
Online Access:	http://dx.doi.org/10.1155/2005/971971
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Conversion to Sirolimus Therapy in Kidney Transplant Recipients with New Onset Diabetes Mellitus after Transplantation
by: Massimiliano Veroux, et al.
Published: (2013-01-01)

Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors
by: Mei Zhan, et al.
Published: (2025-01-01)

Evaluation of COVID-19 protease and HIV inhibitors interactions
by: Tran Linh, et al.
Published: (2022-03-01)

Enhanced Apoptosis of Monocytes from Complication-Free Juvenile-Onset Diabetes Mellitus Type 1 May Be Ameliorated by TNF-α Inhibitors
by: Jolanta Myśliwska, et al.
Published: (2014-01-01)

A multiplex method for rapidly identifying viral protease inhibitors
by: Seo Jung Hong, et al.
Published: (2025-01-01)

Does Diabetes Mellitus Alter the Onset and Clinical Course of Vascular Dementia?
by: Santosh B. Murthy, et al.
Published: (2010-01-01)

Upregulation of FOXO3 in New-Onset Type 1 Diabetes Mellitus
by: Magdalena Zurawek, et al.
Published: (2020-01-01)

JAK inhibitors: a new choice for diabetes mellitus?
by: Mengjun Zhou, et al.
Published: (2025-01-01)

Some Investigations on Protease Enzyme Production Kinetics Using Bacillus licheniformis BBRC 100053 and Effects of Inhibitors on Protease Activity
by: Zahra Ghobadi Nejad, et al.
Published: (2014-01-01)

The Effects of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Disease Risks in Type 2 Diabetes Mellitus
by: Pegah Yousefzadeh, et al.
Published: (2013-01-01)

Efficacy and safety of new protease inhibitor faldaprevir in treatment of hepatitis C
by: M. V. Mayevskaya, et al.
Published: (2013-12-01)

Pretreatment with serine protease inhibitors impairs Leishmania amazonensis survival on macrophages
by: Patrícia de Almeida Machado, et al.
Published: (2025-01-01)

Effects of Pregnancy and Bacterial Vaginosis on Proinflammatory Cytokine and Secretory Leukocyte Protease Inhibitor Concentrations in Vaginal Secretions
by: Jennifer Balkus, et al.
Published: (2010-01-01)

LPS Counter Regulates RNA Expression of Extracellular Proteases and Their Inhibitors in Murine Macrophages
by: Andreas Hald, et al.
Published: (2012-01-01)

Production of Secretory Leucocyte Protease Inhibitor (SLPI) in Human Pancreatic β-Cells
by: Max Nyström, et al.
Published: (1999-01-01)

Streptomyces lavendulae Protease Inhibitor: Purification, Gene Overexpression, and 3-Dimensional Structure
by: D. E. El-Hadedy, et al.
Published: (2015-01-01)

Secretory leukocyte protease inhibitor in punch biopsies from human colonic mucosa
by: Max Nyström, et al.
Published: (2001-01-01)

Potato protease inhibitors, a functional food material with antioxidant and anticancer potential
by: Yaotong Liu, et al.
Published: (2023-09-01)

Structural Analysis of Inhibitor Binding to Enterovirus-D68 3C Protease
by: Vincent N. Azzolino, et al.
Published: (2025-01-01)

Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China
by: J. Ma, et al.
Published: (2014-01-01)

Prolonged Honeymoon Phase in Adult-Onset Type 1 Diabetes Mellitus: A Case Study
by: Pranjali Shah
Published: (2024-04-01)

Secretory Leukocyte Protease Inhibitor Is an Inducible Antimicrobial Peptide Expressed in Staphylococcus aureus Endophthalmitis
by: Victor E. Reviglio, et al.
Published: (2007-01-01)

Real-World Assessment of Weight Change in People with HIV-1 After Initiating Integrase Strand Transfer Inhibitors or Protease Inhibitors
by: Yen-Wen Chen, et al.
Published: (2020-07-01)

An Update of Medical Nutrition Therapy in Gestational Diabetes Mellitus
by: Flavia Cristina Vasile, et al.
Published: (2021-01-01)

Role of Metformin in Preventing New-Onset Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus
by: Yu-Ling Lin, et al.
Published: (2025-01-01)

Bicyclic peptide-enhanced covalent inhibitor of SARS-CoV-2 3CL protease
by: Qian Wang, et al.
Published: (2024-10-01)

The Ability of Secretory Leukocyte Protease Inhibitor to Inhibit Apoptosis in Monocytes Is Independent of Its Antiprotease Activity
by: Niamh McGarry, et al.
Published: (2015-01-01)

Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus
by: Bindu Chamarthi, et al.
Published: (2015-01-01)

Downregulation of Type II Diabetes Mellitus and Maturity Onset Diabetes of Young Pathways in Human Pancreatic Islets from Hyperglycemic Donors
by: Jalal Taneera, et al.
Published: (2014-01-01)

Maternal Infections, Antibiotics, Steroid Use, and Diabetes Mellitus Increase Risk of Early-Onset Sepsis in Preterm Neonates: A Nationwide Population-Based Study
by: Hao-Yuan Lee, et al.
Published: (2025-01-01)

Kidney Disease and Youth Onset Type 2 Diabetes: Considerations for the General Practitioner
by: Allison B. Dart, et al.
Published: (2012-01-01)

Factors in Gestational Diabetes Mellitus Predicting the Needs for Insulin Therapy
by: Ya Zhang, et al.
Published: (2016-01-01)

Exploring covalent inhibitors of SARS-CoV-2 main protease: from peptidomimetics to novel scaffolds
by: Noor Atatreh, et al.
Published: (2025-12-01)

The Effect of Serine Protease Inhibitors on Airway Inflammation in a Chronic Allergen-Induced Asthma Mouse Model
by: Chih-Che Lin, et al.
Published: (2014-01-01)

Alpha-1 Antitrypsin as a Regulatory Protease Inhibitor Modulating Inflammation and Shaping the Tumor Microenvironment in Cancer
by: Siyu Xiang, et al.
Published: (2025-01-01)

Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa
by: Carole L. Wallis, et al.
Published: (2011-01-01)

KCNJ11: Genetic Polymorphisms and Risk of Diabetes Mellitus
by: Polin Haghvirdizadeh, et al.
Published: (2015-01-01)

Previous Gestational Diabetes Mellitus and Markers of Cardiovascular Risk
by: Nikolaos Vrachnis, et al.
Published: (2012-01-01)

Risk factors for type 2 diabetes mellitus in adolescentes
by: Wendy Valdés Gómez, et al.
Published: (2019-06-01)

Assessing hemorrhagic risks in combination therapy: implications of angiogenesis inhibitors and immune checkpoint inhibitors
by: Yuhui Yang, et al.
Published: (2025-02-01)